The French drugmaker’s tyrosine kinase inhibitor has met the progression-free survival primary endpoint in combination with Roche’s Tecentriq in a metastatic prostate cancer trial, edging closer to a large market opportunity after a trio of recent failures in other indications.

With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.

While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.